A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'

Journal of Oncology Pharmacy Practice

Volumn 13, Issue 2, 2007, Pages 119-126

  Kaestner, Sabine ^a   Sewell, Graham ^b,c  

^a University of Bath   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Carboplatin; Dose banding; Sequential temperature; Stability

Indexed keywords

CARBOPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TEMPERATURE; INCUBATION TIME; PARTICULATE MATTER; PH MEASUREMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ROOM TEMPERATURE; STORAGE TEMPERATURE; TEMPERATURE DEPENDENCE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; GLUCOSE; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; LIGHT; TEMPERATURE;

EID: 34548613917     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207080803     Document Type: Article

References (30)

1. Perry MC. The Chemotherapy Source Book 1996, second edition. Baltimore, Williams & Wilkins, 1996.
2. Martindale: The Complete Drug Reference, thirty fifth edition. Pharmaceutical Press, 2007.
3. Carboplatin: Summary of Product Characteristics. Mijdrecht, The Netherlands: Teva Pharma BV, 2003.
4. Schwartz GN, Pendyala L, Kindler H et al. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer 1998; 34: 1543-48.
5. Soo RA, Lim HL, Wang LZ et al. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. Cancer Chemother Pharmacol 2003; 52: 153-58.
6. Obasaju CK, Johnson SW, Rogatko A et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996; 2: 549-52.
7. Siddiqui N, Boddy AV, Thomas HD et al. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 1997; 75: 287-94.
8. Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001; 2: 190-208.
9. Perez EA, Hartmann LC. Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol 1996; 23: 41-45.
10. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
11. Allsopp MA, Sewell GJ. A pharmacokinetic-pharmacodynamic study on carboplatin administered in prolonged continous infusion regimens with synchronous radiotherapy. J Oncol Pharm Pract 1995; 1: 25-32.
12. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522-34.
13. Polee MB. A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res 2004; 10: 1928-34.
14. Allsopp M, Sewell G, Rowland C, Riley C, Schowen R. The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles. Int J Pharm 1991; 69: 197-210.
15. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 317-25.
16. Gust R. Schnurr B. Investigations on the stability of carboplatin infusion solutions. Monatsh Chem 1999; 130: 637-44.
17. Plumridge R, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm 2001; 58: 1760-64.
18. Kaestner S, Sewell G. Pharmacoeconomic aspects of dose-banding. Hospital Pharmacy Europe 2006; 26: 33-34.
19. Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham NHS Trust. J Oncol Pharm Pract 1998; 4: 10-14.
20. So J. Improving the lives of patients with cancer. Pharm Manage 2002; 18: 27-29.
21. MacLean F, MacIntyre J, McDade J, Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J 2003; 270: 691-93.
22. Allwood M, Stanley A, Wright P eds. The Cytotoxics Handbook, fourth edition. Radcliffe Medical Press, 2002: 276-81 and 286-90.
23. Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003; 28: 349-53.
24. Kaestner S, Sewell G. Dose-banding of carboplatin: rationale and proposed banding scheme. J Oncol Pharm Pract 2007; 13: 109-17.
25. Kaestner SA. Studies on dose-banding of cancer chemotherapy. Thesis. University of Bath, 2007.
26. Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007 - the 'Orange Guide'. Pharmaceutical Press, 2007.
27. British Pharmacopoeia. The Stationery Office, 2006.
28. Sewell G, Allsopp M, Collinson M, Tyrrell C, Prentice A, Copplestone J. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994; 19: 127-33.
29. Notes for Guidance on Stability Testing: Stability Testing of New Drug Substances and Products 2003, CPMP/ICH/2736/99 European Medicines Evaluation Agency, London.
30. Sewell GJ. Drugs prescribed: licensing and registration. In Payne J, James J, Byard RW, Corey TS, Henderson C eds. Encyclopaedia of Forensic and Legal Medicine 2005. Elsevier, 2005: 239-42.